Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2016 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping.
Schildcrout JS, Denny JC, Bowton E, Gregg W, Pulley JM, Basford MA, Cowan JD, Xu H, Ramirez AH, Crawford DC, Ritchie MD, Peterson JF, Masys DR, Wilke RA, Roden DM. Schildcrout JS, et al. Clin Pharmacol Ther. 2012 Aug;92(2):235-42. doi: 10.1038/clpt.2012.66. Epub 2012 Jun 27. Clin Pharmacol Ther. 2012. PMID: 22739144 Free PMC article.
Routine integration of genotype data into drug decision making could improve patient safety, particularly if many relevant genetic variants can be assayed simultaneously before prescribing the target drug. ...Our results suggest that multiplexed, preemptiv
Routine integration of genotype data into drug decision making could improve patient safety, particularly if many relevant gen …
Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs.
Picard N, Bergan S, Marquet P, van Gelder T, Wallemacq P, Hesselink DA, Haufroid V. Picard N, et al. Ther Drug Monit. 2016 Apr;38 Suppl 1:S57-69. doi: 10.1097/FTD.0000000000000255. Ther Drug Monit. 2016. PMID: 26469711 Review.
In association with therapeutic drug monitoring of immunosuppressive drugs, pharmacogenetics has rapidly emerged as an additional tool to refine dose selection or, more interestingly to select, a priori, the first dose to administer. ...The main reason is probably t …
In association with therapeutic drug monitoring of immunosuppressive drugs, pharmacogenetics has rapidly emerged as an additio …
Feedback